Pediatric Glioblastoma Therapies Based on Patient-Derived Stem Cell Resources
Annual rept. 1 Sep 2012-31 Aug 2013
FRED HUTCHINSON CANCER RESEARCH CENTER SEATTLE WA
Pagination or Media Count:
Gliomas comprise 60 of cases among pediatric brain tumors. To date, there are few resources available to study and manipulate pediatric brain tumor cells, to evaluate whether pediatric tumor will have fundamental different responses to the new therapeutic regimes. Since glioma stem cell lines have been successfully isolated from adults, in this proposal we aim to isolate and characterize GSC populations from pediatric patients. In the past two years we have successfully derived and cultured eight patient-derived pediatric glioma stem cell lines. In the past year we have continued molecular and phenotypic characterization of these lines. This characterization included analysis of gene expression and patient-specific gene mutations, and also proof-of-concept shRNA screens. In addition we have begun to identify candidate therapeutic targets using the pediatric GBM isolates. So far, this effort has led to two promising candidate molecules for precision pediatric brain tumor therapeutics.
- Anatomy and Physiology
- Medicine and Medical Research